You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
榮昌生物(09995.HK)擬折價9.51%配售1900萬股H股 總籌8億港元加碼核心產品管線
格隆匯 05-22 07:51

格隆匯5月22日丨榮昌生物(09995.HK)發佈公吿,2025年5月22日(開市時間前),公司與配售代理(即摩根士丹利及華泰國際)訂立了配售協議,根據配售協議所列條款並在配售協議所列條件的規限下,公司同意按配售價發行配售股份,而配售代理已分別單獨同意作為公司的代理,按盡力基準促使承配人按配售價購買配售股份。配售股份將根據一般授權配發及發行。

公司將根據配售協議的條款並遵守其中的條件,發行1900萬股新H股。每股配售股份的配售價42.44港元較5月21日(即最後交易日及釐定配售價當日)於聯交所所報的收市價每股H股46.90港元折讓約9.51%。配售股份相當於現有已發行約1.896億股H股的約10.02%,及於本公吿日期已發行股份總數的約3.49%。假設從本公吿日期起至配售完成,除發行配售股份外,本公司已發行股本沒有其他變化,則配售股份約佔經擴大已發行H股數目的約9.11%及配售股份配發及發行後經擴大已發行股份總數的約3.37%。

假設所有配售股份已獲配售,配售所得款項總額預計約為8.06億港元,而配售所得款項淨額(扣除佣金及估計開支後)預計約為7.96億港元。集團擬將配售所得款項淨額用於投資核心產品泰它西普(RC18)的核心適應症拓展,如重症肌無力、膜性腎病及其他一般企業用途。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account